Sofinnova Partners SAS - Jan 11, 2022 Form 4 Insider Report for CinCor Pharma, Inc. (CINC)

Role
10%+ Owner
Signature
Sofinnova Partners SAS, By /s/ Monique Saulnier, Managing Partner
Stock symbol
CINC
Transactions as of
Jan 11, 2022
Transactions value $
$3,520,000
Form type
4
Date filed
1/13/2022, 03:36 PM
Previous filing
Jan 6, 2022
Next filing
Aug 17, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CINC Common Stock Conversion of derivative security +3.87M 3.87M Jan 11, 2022 By Sofinnova Capital IX F1, F2
transaction CINC Common Stock Purchase $3.52M +220K +5.69% $16.00 4.09M Jan 11, 2022 By Sofinnova Capital IX F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CINC Series A Preferred Stock Conversion of derivative security $0 -10M -100% $0.00* 0 Jan 11, 2022 Common Stock 2.94M By Sofinnova Capital IX F1, F2
transaction CINC Series B Preferred Stock Conversion of derivative security $0 -3.15M -100% $0.00* 0 Jan 11, 2022 Common Stock 926K By Sofinnova Capital IX F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO") for no additional consideration, on a 3.4:1 basis, and had no expiration date.
F2 The shares are directly held by Sofinnova Capital IX ("SC IX"). Sofinnova Partners SAS ("Sofinnova Partners") is the management company of SC IX and may be deemed to share voting and investment power over the shares held by SC IX. Sofinnova Partners disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein.